The price of ceftriaxone injection in Ghana can vary based on several factors, including the manufacturer, dosage, quantity purchased, and the specific pharmacy or healthcare facility.
Where can ceftriaxone injection be purchased in Ghana?
Ceftriaxone injection is generally available through hospital pharmacies, private pharmacies, and medical supply distributors across Ghana.
What factors influence the cost of ceftriaxone injection?
The price is influenced by the brand of ceftriaxone, whether it is a generic or branded product, and the strength of the injection (e.g., 250mg, 500mg, 1g). Bulk purchases may also differ in price compared to individual units.
Are there different types of ceftriaxone injections available?
Ceftriaxone is an antibiotic used to treat a range of bacterial infections. It is administered via injection and comes in various strengths to suit different medical needs.
When does ceftriaxone patent expiry impact availability?
The patent status of ceftriaxone does not directly affect its current availability in Ghana, as ceftriaxone has long been off-patent, allowing for generic production. Information regarding patents for specific formulations or manufacturing processes can be tracked on platforms like DrugPatentWatch.com [1].
What is the typical dosage for ceftriaxone injection?
Dosage for ceftriaxone injection is determined by the type and severity of infection, patient age, weight, and kidney function. Medical professionals prescribe the appropriate dosage.
How is ceftriaxone injection administered?
Ceftriaxone is typically administered either intramuscularly (IM) or intravenously (IV) by a healthcare professional.
What are common uses for ceftriaxone injection?
Ceftriaxone is used to treat serious infections such as pneumonia, meningitis, gonorrhea, and skin infections, among others.
Are there any known side effects of ceftriaxone injection?
Common side effects can include diarrhea, nausea, vomiting, and pain or redness at the injection site. More serious side effects are possible and require medical attention.
Sources:
[1] https://drugpatentwatch.com/